AbCellera Biologics Inc. (ABCL) Financial Ratios

AbCellera Biologics Inc. (ABCL) has an ST Score of 53.2 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate ABCL a Buy, with a price target of $14.75 (+16.6% vs the current price). Our ST Score grades it B- (53.2/100). The ST Score is a data-driven signal, not a recommendation.

Valuation C, Profitability A-, Financial Strength B, Momentum A-, Growth F, Forecast B+.

AbCellera Biologics Inc. (ABCL) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

AbCellera Biologics Inc. (ABCL) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

AbCellera Biologics Inc. (ABCL) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

AbCellera Biologics Inc. (ABCL) earns a financial strength grade of B, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for AbCellera Biologics Inc. (ABCL) is $14.75 from 12 analysts, which is +16.6% versus the recent price of $12.65.

AbCellera Biologics Inc. (ABCL) has a Piotroski F-Score of 3 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.